These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 35149540)

  • 21. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
    Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier.
    Shan Y; Cen Y; Zhang Y; Tan R; Zhao J; Nie Z; Zhang J; Yu S
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):279-289. PubMed ID: 35112329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
    Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
    Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the role of nucleoside transporters, P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in the placental transport of entecavir using in vitro, ex vivo, and in situ methods.
    Cerveny L; Karbanova S; Karahoda R; Horackova H; Jiraskova L; Ali MNH; Staud F
    Toxicol Appl Pharmacol; 2023 Mar; 463():116427. PubMed ID: 36801311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.
    Liao MZ; Gao C; Shireman LM; Phillips B; Risler LJ; Neradugomma NK; Choudhari P; Prasad B; Shen DD; Mao Q
    Pharmacol Res; 2017 May; 119():61-71. PubMed ID: 28111265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical Application of Rodent Transporter Knockout Models to Assess Brain Penetration in Drug Discovery.
    Eneberg E; Jones CR; Jensen T; Langthaler K; Bundgaard C
    Drug Metab Bioanal Lett; 2022; 15(1):12-21. PubMed ID: 35196975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics.
    Anoshchenko O; Prasad B; Neradugomma NK; Wang J; Mao Q; Unadkat JD
    Drug Metab Dispos; 2020 Sep; 48(9):735-741. PubMed ID: 32591415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
    Chatterjee S; Deshpande AA; Shen H
    Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
    Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
    Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome.
    Anoshchenko O; Milad MA; Unadkat JD
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1057-1070. PubMed ID: 34273255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages.
    Mathias AA; Hitti J; Unadkat JD
    Am J Physiol Regul Integr Comp Physiol; 2005 Oct; 289(4):R963-9. PubMed ID: 15961534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.
    Zhang Z; Imperial MZ; Patilea-Vrana GI; Wedagedera J; Gaohua L; Unadkat JD
    Drug Metab Dispos; 2017 Aug; 45(8):920-938. PubMed ID: 28588050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transplacental Pharmacokinetic Model of Digoxin Based on Ex Vivo Human Placental Perfusion Study.
    Kurosawa K; Noguchi S; Nishimura T; Tomi M; Chiba K
    Drug Metab Dispos; 2022 Mar; 50(3):287-298. PubMed ID: 34903589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
    Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
    BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
    Iwasaki S; Kosugi Y; Zhu AZX; Nakagawa S; Sano N; Funami M; Kosaka M; Furuta A; Hirabayashi H; Amano N
    Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunolocalization of ABC drug transporters in human placenta from normal and gestational diabetic pregnancies.
    Kozłowska-Rup D; Czekaj P; Plewka D; Sikora J
    Ginekol Pol; 2014 Jun; 85(6):410-9. PubMed ID: 25029804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
    Colclough N; Alluri RV; Tucker JW; Gozalpour E; Li D; Du H; Li W; Harlfinger S; O'Neill DJ; Sproat GG; Chen K; Yan Y; McGinnity DF
    Drug Metab Dispos; 2024 Jan; 52(2):95-105. PubMed ID: 38071533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.